AVXL Anavex Life Sciences Corp

Price (delayed)

$3.44

Market cap

$282.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.55

Enterprise value

$138.7M

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, ...

Highlights

The company's EPS rose by 15% YoY and by 8% QoQ

Anavex Life Sciences's net income has increased by 14% YoY and by 9% QoQ

AVXL's quick ratio is up by 6% YoY but it is down by 4.5% QoQ

Anavex Life Sciences's equity has decreased by 4.4% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://anavex.com

Peers: LGND ABIO CORT PTN

Key stats

What are the main financial stats of AVXL

Market

Shares outstanding

82.11M

Market cap

$282.47M

Enterprise value

$138.7M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.08

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$43.04M

EBITDA

-$43.04M

Free cash flow

-$29.31M

Per share

EPS

-$0.55

Free cash flow per share

-$0.36

Book value per share

$1.65

Revenue per share

TBVPS

$1.8

Balance sheet

Total assets

$148.07M

Total liabilities

$12.5M

Debt

Equity

$135.58M

Working capital

$135.58M

Liquidity

Debt to equity

Current ratio

11.85

Quick ratio

11.51

Net debt/EBITDA

3.34

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-27.9%

Return on equity

-30.3%

Return on invested capital

N/A

Return on capital employed

-31.7%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

AVXL stock price

How has the Anavex Life Sciences stock price performed over time

Intraday

1.47%

1 week

-8.99%

1 month

-28.93%

1 year

-58.25%

YTD

-63.05%

QTD

-32.42%

Financial performance

How have Anavex Life Sciences's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$51.67M

Net income

-$43.16M

Gross margin

N/A

Net margin

N/A

Anavex Life Sciences's net income has increased by 14% YoY and by 9% QoQ

AVXL's operating income is up by 7% since the previous quarter and by 5% year-on-year

Growth

What is Anavex Life Sciences's growth rate over time

Valuation

What is Anavex Life Sciences stock price valuation

P/E

N/A

P/B

2.08

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

The company's EPS rose by 15% YoY and by 8% QoQ

The stock's price to book (P/B) is 72% less than its 5-year quarterly average of 7.5 and 55% less than its last 4 quarters average of 4.6

Anavex Life Sciences's equity has decreased by 4.4% QoQ

Efficiency

How efficient is Anavex Life Sciences business performance

AVXL's return on assets is up by 13% year-on-year and by 9% since the previous quarter

The ROE has grown by 12% YoY and by 9% from the previous quarter

Dividends

What is AVXL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AVXL.

Financial health

How did Anavex Life Sciences financials performed over time

AVXL's quick ratio is up by 6% YoY but it is down by 4.5% QoQ

Anavex Life Sciences's total liabilities has decreased by 6% YoY

The debt is 100% smaller than the equity

Anavex Life Sciences's equity has decreased by 4.4% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.